Silence Therapeutics receives US$2mln as Mallinckrodt collaboration moves onto third drug targetProactive Investors • 02/26/21
Mallinckrodt (MNKKQ) Stock Sinks As Market Gains: What You Should KnowZacks Investment Research • 02/11/21
Mallinckrodt Earns Top Marks in Human Rights Campaign's 2021 Corporate Equality IndexPRNewsWire • 01/29/21
The Buxton Helmsley Group Announces Sufficient Shareholder Backing to Call Mallinckrodt Meeting of Shareholders, Begin Realigning Board and Management with Shareholder Interests, Renegotiate Restructuring PlanPRNewsWire • 01/27/21
The Buxton Helmsley Group to Call Meeting of Mallinckrodt Shareholders to Realign Board and Management with Shareholder Interests, Renegotiate Restructuring PlanPRNewsWire • 01/15/21
